Deshpande Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.25 M
- Company Age 9 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.35 Cr
- Satisfied Charges ₹ 5.00 M
- Revenue Growth 20.45%
- Profit Growth 168.04%
- Ebitda -142.24%
- Net Worth 9.04%
- Total Assets 9.04%
About Deshpande Drugs
Deshpande Drugs Private Limited (DDPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 October 2015 (Nine years and four months 23 days old ). Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.25 M.
The company currently has active open charges totaling ₹1.35 Cr. The company has closed loans amounting to ₹5.00 M, as per Ministry of Corporate Affairs (MCA) records.
Suma Nagendra, Jahnavi Amarnath, and Kashipathi Poornima serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51103KA2015PTC083096
- Company No.
083096
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Oct 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Deshpande Drugs?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suma Nagendra  | Director | 09-Jun-2016 | Current |
| Kashipathi Poornima | Director | 09-Jun-2016 | Current |
| Jahnavi Amarnath | Director | 09-Jun-2016 | Current |
Financial Performance of Deshpande Drugs.
Deshpande Drugs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 20.45% increase. The company also saw a substantial improvement in profitability, with a 168.04% increase in profit. The company's net worth moved up by a moderate rise of 9.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Deshpande Drugs?
In 2021, Deshpande Drugs had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹13.50 M
₹5.00 M
Charges Breakdown by Lending Institutions
- Others : 1.35 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 22 Feb 2019 | Others | ₹1.35 Cr | Open |
| 23 Aug 2017 | Others | ₹5.00 M | Satisfied |
How Many Employees Work at Deshpande Drugs?
Unlock and access historical data on people associated with Deshpande Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Deshpande Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Deshpande Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
